Generic Name and Formulations:
Crisaborole 2%; oint.
Anacor Pharmaceuticals, Inc.
Indications for EUCRISA:
Mild-to-moderate atopic dermatitis.
Adults and Children:
<2yrs: not established. ≥2yrs: apply a thin layer twice daily to affected areas.
Not for ophthalmic, oral, intravaginal use. Discontinue immediately if hypersensitivity occurs. Pregnancy. Nursing mothers.
Phosphodiesterase 4 (PDE4) inhibitor.
Application site pain (eg, burning, stinging); hypersensitivity reactions, contact urticaria.
Endocrinology Advisor Articles
- Higher BUN May Increase Risk for Incident Diabetes
- Efficacy of Novel GLP-1 Receptor Agonist Drug Device Examined
- Takeout Food May Increase Adverse Health Consequences in Children
- Nonhormonal Options Available for Menopause Symptom Relief
- Plasma Volume Changes Mediate Risk of CV Mortality With Empagliflozin
- New Consensus Recommendations on Use of Continuous Glucose Monitoring
- Does Genetic Susceptibility Lead to Late-Onset Type 1 Diabetes?
- Clinical Outcomes in T2D: Low-Carbohydrate vs Calorie-Restricted Diet
- New Continuous Glucose Monitoring System Now Available for Medicare Patients
- Text Message-Delivered Interventions Effective for Weight Management
- Effect of Intra-Articular Depot Betamethasone on Insulin Resistance in T2D
- Gastric Bypass vs Sleeve Gastrectomy Outcomes in Morbid Obesity
- Acute Kidney Injury Increases Risk for Postdischarge Hypoglycemia in Diabetes
- Novel Deep Learning System May Help Identify Diabetic Retinopathy
- Trends in CVD, Risk Factors, and Medications in Children With T1D